» Articles » PMID: 31953475

Δ9-tetrahydrocannabinol Exposure During Rat Pregnancy Leads to Symmetrical Fetal Growth Restriction and Labyrinth-specific Vascular Defects in the Placenta

Overview
Journal Sci Rep
Specialty Science
Date 2020 Jan 19
PMID 31953475
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

1 in 5 women report cannabis use during pregnancy, with nausea cited as their primary motivation. Studies show that (-)-△9-tetrahydrocannabinol (Δ9-THC), the major psychoactive ingredient in cannabis, causes fetal growth restriction, though the mechanisms are not well understood. Given the critical role of the placenta to transfer oxygen and nutrients from mother, to the fetus, any compromise in the development of fetal-placental circulation significantly affects maternal-fetal exchange and thereby, fetal growth. The goal of this study was to examine, in rats, the impact of maternal Δ9-THC exposure on fetal development, neonatal outcomes, and placental development. Dams received a daily intraperitoneal injection (i.p.) of vehicle control or Δ9-THC (3 mg/kg) from embryonic (E)6.5 through 22. Dams were allowed to deliver normally to measure pregnancy and neonatal outcomes, with a subset sacrificed at E19.5 for placenta assessment via immunohistochemistry and qPCR. Gestational Δ9-THC exposure resulted in pups born with symmetrical fetal growth restriction, with catch up growth by post-natal day (PND)21. During pregnancy there were no changes to maternal food intake, maternal weight gain, litter size, or gestational length. E19.5 placentas from Δ9-THC-exposed pregnancies exhibited a phenotype characterized by increased labyrinth area, reduced Epcam expression (marker of labyrinth trophoblast progenitors), altered maternal blood space, decreased fetal capillary area and an increased recruitment of pericytes with greater collagen deposition, when compared to vehicle controls. Further, at E19.5 labyrinth trophoblast had reduced glucose transporter 1 (GLUT1) and glucocorticoid receptor (GR) expression in response to Δ9-THC exposure. In conclusion, maternal exposure to Δ9-THC effectively compromised fetal growth, which may be a result of the adversely affected labyrinth zone development. These findings implicate GLUT1 as a Δ9-THC target and provide a potential mechanism for the fetal growth restriction observed in women who use cannabis during pregnancy.

Citing Articles

Maternal dietary DHA and EPA supplementation ameliorates adverse cardiac outcomes in THC-exposed rat offspring.

Lee K, Sarikahya M, Cousineau S, Yeung K, Lucas A, Loudon K Sci Rep. 2025; 15(1):8316.

PMID: 40064971 PMC: 11894106. DOI: 10.1038/s41598-025-92844-6.


Early Life Outcomes of Prenatal Exposure to Alcohol and Synthetic Cannabinoids in Mice.

Rouzer S, Domen M, George A, Bowring A, Miranda R bioRxiv. 2025; .

PMID: 39975197 PMC: 11838379. DOI: 10.1101/2025.01.27.635118.


Evaluation of the Association Between Prenatal Cannabis Use and Risk of Developmental Delay.

Watts D, Lebel C, Chaput K, Giesbrecht G, Dewsnap K, Baglot S JAACAP Open. 2024; 2(4):250-262.

PMID: 39697398 PMC: 11650681. DOI: 10.1016/j.jaacop.2024.03.004.


Impact of prenatal exposure to delta 9-tetrahydrocannabinol and cannabidiol on birth size and postnatal growth trajectories.

Moore B, Mueller N, Perng W, Sauder K, Hebert E, Hoyt A Pediatr Obes. 2024; 20(1):e13187.

PMID: 39681476 PMC: 11669837. DOI: 10.1111/ijpo.13187.


Prenatal cannabis exposure in the clinic and laboratory: What do we know and where do we need to go?.

Cupo L, Dominguez-Cancino K, Nazif-Munoz J, Chakravarty M Drug Alcohol Depend Rep. 2024; 13:100282.

PMID: 39430603 PMC: 11490891. DOI: 10.1016/j.dadr.2024.100282.


References
1.
Jarlenski M, Koma J, Zank J, Bodnar L, Bogen D, Chang J . Trends in perception of risk of regular marijuana use among US pregnant and nonpregnant reproductive-aged women. Am J Obstet Gynecol. 2017; 217(6):705-707. PMC: 5971084. DOI: 10.1016/j.ajog.2017.08.015. View

2.
Young-Wolff K, Tucker L, Alexeeff S, Armstrong M, Conway A, Weisner C . Trends in Self-reported and Biochemically Tested Marijuana Use Among Pregnant Females in California From 2009-2016. JAMA. 2017; 318(24):2490-2491. PMC: 5769923. DOI: 10.1001/jama.2017.17225. View

3.
Richardson G, Ryan C, Willford J, Day N, Goldschmidt L . Prenatal alcohol and marijuana exposure: effects on neuropsychological outcomes at 10 years. Neurotoxicol Teratol. 2002; 24(3):309-20. DOI: 10.1016/s0892-0362(02)00193-9. View

4.
Corsi D, Hsu H, Weiss D, Fell D, Walker M . Trends and correlates of cannabis use in pregnancy: a population-based study in Ontario, Canada from 2012 to 2017. Can J Public Health. 2018; 110(1):76-84. PMC: 6335373. DOI: 10.17269/s41997-018-0148-0. View

5.
Gunn J, Rosales C, Center K, Nunez A, Gibson S, Christ C . Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016; 6(4):e009986. PMC: 4823436. DOI: 10.1136/bmjopen-2015-009986. View